MedTrace Logo

Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)

NCT00212316 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-08-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and clinical impact of 15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay the groundwork for possible subsequent trials designed to specifically address its ability to slow or halt the progression of the disease.

Conditions

Interventions

DRUG

sodium phenylbutyrate

Sponsors & Collaborators

  • HP Therapeutics Foundation

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • Columbia University

    collaborator OTHER

  • University of Iowa

    collaborator OTHER

  • University of California, San Diego

    collaborator OTHER

  • University of Kansas

    collaborator OTHER

  • University of Alabama at Birmingham

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • University of Rochester

    lead OTHER

Principal Investigators

  • Steven M. Hersch, MD, PhD · Co-Chair, Huntington Study Group, Massachusetts General Hospital

  • Karl Kieburtz, MD, MPH · Director, Clinical Trials Coordination Center, University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212316 on ClinicalTrials.gov